Head-to-head · free
Alnylam Pharmaceuticals vs Joint Stock Company Kaspi.kz
ALNY vs KSPI — return on capital, cash generation, margins and balance sheet side by side.
ALNY
3 / 5
measures where ALNY leads
KSPI
2 / 5
measures where KSPI leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ALNY · FY2025 | KSPI |
|---|---|---|
| Revenue | $3.7B | — |
| Net income | (18.3M) | — |
| Revenue growth (yearly, multi-year) | 44.8% | — |
| Free cash flow | $465.4M | — |
| Free cash flow margin | 12.5% | — |
| Net cash / (debt) | — | — |
| ROIC | 28.4% | 42.8% |
| Return on equity | 73.3% | 53.5% |
| Gross margin | 81.6% | 47.4% |
| Operating margin | 13.5% | 32.6% |
| Net debt / EBITDA | -1.17x | -0.35x |
Figures are as reported by each company; latest fiscal year shown.
Where Alnylam Pharmaceuticals's cash went (FY2025)
- Capital spending
- $58.7M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free